Evidence map›Paper›PMID 34979042›Full record

ArticleJournal of clinical laboratory analysis2022

Early platelet elevation after complete remission as a prognostic marker of favourable outcomes in favourable- and intermediate-risk acute myeloid leukaemia: A retrospective study.

Xiaoling Wen, Ruoqi Li, Xialin Zhang, Jiahong Zhai, Suxia Yang, Yaozi Wang, Yanhong Tan, Zhifang Xu, Linhua Yang, Ruijuan Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xiaoling WenDepartment of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.ORCID https://orcid.org/0000-0001-7300-4027
Ruoqi LiDepartment of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Xialin ZhangDepartment of Hematology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences，Tongji Shanxi Hospital, Taiyuan, China.
Jiahong ZhaiDepartment of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Suxia YangDepartment of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Yaozi WangDepartment of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Yanhong TanDepartment of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Zhifang XuDepartment of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Linhua YangDepartment of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Ruijuan ZhangDepartment of Hematology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences，Tongji Shanxi Hospital, Taiyuan, China.
Shanxi Medical University · CN

Funding

Shanxi Key Research and Development Project 201903D321133
6 · The paper itself

Abstract

objectivesPlatelet (PLT) recovery after chemotherapy is associated with the prognosis of patients with acute myeloid leukaemia (AML). This study aimed to explore the prognostic significance of early high PLT values in patients with de novo non-M3 AML who achieved first complete remission (CR).

methodsA total of 206 patients with de novo non-M3 AML were analysed in this retrospective study. A receiver operating characteristic (ROC) curve was used to determine the optimal PLT cut-off. The overall survival (OS) and relapse-free survival (RFS) were assessed using Kaplan-Meier and Cox regression analyses.

results312×10

conclusionOur results showed that early high PLT count recovery at first CR in non-adverse-risk AML patients is a positive prognostic marker for survival outcomes.

Indexed as

Induction ChemotherapyPlatelet CountAdolescentAdultAgedChildFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLeukemia, MyeloidMaleMiddle AgedPrognosisRemission InductionRetrospective Studiesacute myeloid leukaemiaoutcomeoverall survivalplateletrelapse-free survival

Identifiers

PMID34979042
PMCPMC8841180
OpenAlexW4205235975

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.